EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer

SIMPLE SUMMARY: Lung cancer that is driven by mutations in the epidermal growth factor receptor (EGFR) is currently treated with tyrosine kinase inhibitors (TKIs). Although patients initially respond well to TKI treatment, drug resistance against EGFR-targeted therapy emerges. Attempts to combine im...

Descripción completa

Detalles Bibliográficos
Autores principales: Selenz, Carolin, Compes, Anik, Nill, Marieke, Borchmann, Sven, Odenthal, Margarete, Florin, Alexandra, Brägelmann, Johannes, Büttner, Reinhard, Meder, Lydia, Ullrich, Roland T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406398/
https://www.ncbi.nlm.nih.gov/pubmed/36010935
http://dx.doi.org/10.3390/cancers14163943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406398/
https://www.ncbi.nlm.nih.gov/pubmed/36010935
http://dx.doi.org/10.3390/cancers14163943

Ejemplares similares